These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 29982712)
21. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296 [TBL] [Abstract][Full Text] [Related]
22. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003 [TBL] [Abstract][Full Text] [Related]
23. Primary Sjogren's syndrome: current and prospective therapies. Thanou-Stavraki A; James JA Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766 [TBL] [Abstract][Full Text] [Related]
24. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785 [TBL] [Abstract][Full Text] [Related]
25. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA; Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774 [TBL] [Abstract][Full Text] [Related]
26. Determinants of diagnosis and disease course in primary Sjögren's syndrome: Results from datamining of electronic health records. Sandhya P; Janardana R; Sudarsanam T; Mahasampath G; Prakash JAJ; Danda D Int J Rheum Dis; 2019 Sep; 22(9):1768-1774. PubMed ID: 31328441 [TBL] [Abstract][Full Text] [Related]
27. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review. Wise LM; Arkfeld DG Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212 [TBL] [Abstract][Full Text] [Related]
28. Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome. Liu Y; Liao X; Wang Y; Chen S; Sun Y; Lin Q; Shi G Oncotarget; 2017 Feb; 8(9):14306-14313. PubMed ID: 28147328 [TBL] [Abstract][Full Text] [Related]
29. Predicting lymphoma development in patients with Sjögren's syndrome. De Vita S; Gandolfo S Expert Rev Clin Immunol; 2019 Sep; 15(9):929-938. PubMed ID: 31347413 [No Abstract] [Full Text] [Related]
30. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131 [TBL] [Abstract][Full Text] [Related]
31. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome. Verstappen GM; Meiners PM; Corneth OBJ; Visser A; Arends S; Abdulahad WH; Hendriks RW; Vissink A; Kroese FGM; Bootsma H Arthritis Rheumatol; 2017 Sep; 69(9):1850-1861. PubMed ID: 28564491 [TBL] [Abstract][Full Text] [Related]